Senolytic vaccine (anti-GPNMB) dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Senolytic vaccine (anti-GPNMB) is a vaccine that trains the immune system to attack GPNMB, a protein found in high amounts on worn-out 'zombie' cells. In mice it removed cells carrying GPNMB and helped male mice bred to age too fast live longer. There is no human study.
Evidence grade for Senolytic vaccine (anti-GPNMB): Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 3 animal studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 animal studies, no human study
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Ageing and longevity, Immune system and inflammation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a vaccine that trains the immune system to attack GPNMB, a protein found on worn-out 'zombie' cells. It has only been tested in mice. There is no human study and no product.
What people take it for
- A shot that slows ageing.
- Clearing zombie cells without a daily drug.
What studies in people showed
Nobody has tested it in people. In mice, the vaccine cleared cells carrying GPNMB and helped male mice bred to age too fast live longer. That was not normal mice, and not females. Later, the same team found GPNMB helps those cells survive. Removing it made blood vessel disease in mice worse.
What people report
Reports, not study results
The good
- We have not collected user reports on this one. Nobody can get it.
The bad
- In mice, removing GPNMB made blood vessel disease worse.
- GPNMB is also found on healthy cells, so the immune system could hit them too.
Where these come from: The bad lines come from the mouse studies and notes on this page. We have not collected user reports on this one, because nobody can get it.
My bottom line
An anti-ageing vaccine makes a great headline. The real result is fast-ageing male mice. There is nothing here for a person to act on yet.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Living longer2 animal or lab studies
- Immune function1 animal or lab study
34 of the 36 indexed goals have no study of any kind behind Senolytic vaccine (anti-GPNMB)
No study in people, animals or cells on this page reports a result for these. That does not prove Senolytic vaccine (anti-GPNMB) does nothing for them. It does mean anything you have heard about Senolytic vaccine (anti-GPNMB) and one of these did not come from a study cited here.
Show full evidence
What is Senolytic vaccine (anti-GPNMB)?
Senolytic vaccine (anti-GPNMB) is a vaccine that trains the immune system to attack GPNMB, a protein found in high amounts on worn-out 'zombie' cells. In mice it removed cells carrying GPNMB and helped male mice bred to age too fast live longer. There is no human study.
A Japanese team at Juntendo and Niigata universities published this in Nature Aging in 2021. The headline wrote itself: a vaccine against ageing. What they did is narrower, and more interesting, than the headline.
It starts from a complaint about current senolytic drugs. Most work by blocking the survival switches that keep cells alive. Healthy cells use those switches too, so harm to healthy tissue is a real worry. The other way is to find something on the surface of a zombie cell that is not on a healthy one, and let the immune system do the killing. The team searched gene activity data from zombie cells taken from human blood vessel linings. They picked GPNMB, a protein that sits in the cell wall and is found in high amounts on zombie cells. GPNMB was also higher in the blood vessel lining cells and white blood cells of people and mice with clogged arteries.
Then they did three things in mice. Wiping out cells that carried GPNMB, by changing the mice's genes, cut zombie cells in fat and improved blood sugar and fat problems in mice on a high-fat diet. It also cut artery clogging in mice bred to get it. Vaccinating mice against GPNMB cut the number of cells carrying it. And the vaccine improved signs of normal and disease-driven ageing, and made male mice bred to age too fast live longer.
Read that last part carefully, because it is often got wrong. The longer life was in male mice genetically built to age abnormally fast. Not normal mice, and not both sexes. Later work from the same team makes it messier. GPNMB turns out to help zombie cells survive by protecting the cell's recycling bins, called lysosomes. Removing it in mice hurt blood vessel function and made artery clogging worse. The protein you would vaccinate against is doing something protective in the cells that carry it.
No human study exists. A registry search finds no study of a GPNMB senolytic vaccine.
How does Senolytic vaccine (anti-GPNMB) work?
GPNMB is a protein that pokes through the cell wall and is found in high amounts on zombie cells. That makes it a tag the immune system can be trained to spot. The vaccine raises antibodies and immune cells against GPNMB, so the body clears cells that carry it, instead of a drug doing it. The appeal is that the killing uses machinery the body already has. Immune memory could, in theory, keep clearing new zombie cells long after one course of shots. The catch, shown by the same team: GPNMB itself helps zombie cells survive by protecting their lysosomes. So the target is not just a harmless flag.
The state of the research
There is no human evidence. No study of a GPNMB senolytic vaccine is registered, and nothing has been given to a person.
The honest version of this page: the vaccine idea is good, and the target is not settled. GPNMB is found in high amounts on zombie cells, which is what makes it useful. It is also something those cells need to survive. The same lab showed that a year later, when removing it made blood vessel disease in mice worse. GPNMB is also found in healthy tissue, including skin pigment cells, bone-clearing cells and some immune cells. Cancer researchers study it as a tumour target too, which is another way of saying it is not only on zombie cells. An immune response you cannot switch off, aimed at a tag healthy tissue also carries, is a very different safety bet from a drug that is half gone in three hours.
Quote the lifespan claim exactly. It is male mice bred to age abnormally fast. It is not normal mice, it is not females, and it is not people.
Senolytics are drugs meant to clear out worn-out 'zombie' cells, called senescent cells. No senolytic of any kind has yet made people better off in a proper human study against a dummy treatment. That is the most useful fact to carry into any senolytic talk. One pair, dasatinib plus quercetin, has lowered the number of zombie cells in people, measured in skin and fat samples. What has not followed is a study where people who got a senolytic walked further, broke fewer bones or lived longer than people who did not. The two studies against a dummy that tried, one in lung scarring (pulmonary fibrosis) and one on bone turnover after menopause, found no difference.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 3 animal studies. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 3 sources here are studies in people.
- Animal study · done in animals3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2021 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not applicable. A vaccine is dosed as a course and its effect depends on the immune response it raises, not on clearance of the injected material.
No amino acid sequence is on file for Senolytic vaccine (anti-GPNMB), so none is drawn rather than guessed from a name.
The studies we cite
- Animal study2021Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice
In mice. The team found GPNMB on zombie cells. Removing cells that carried it eased fat and blood sugar problems in mice on a high-fat diet and cut artery clogging. A vaccine against it cut those cells and helped male mice bred to age too fast live longer.
Mouse. Identified GPNMB as a seno-antigen enriched in senescent cells. Genetic ablation of Gpnmb-positive cells attenuated adipose senescence and improved systemic metabolic abnormalities in high-fat-diet mice and reduced atherosclerotic burden in ApoE knockout mice. Immunisation against Gpnmb reduced Gpnmb-positive cells, improved age-related phenotypes, and extended the male lifespan of progeroid mice.
- Animal study2022Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells
In human blood vessel cells in a dish and in mice. The same team found that GPNMB helps zombie cells survive. Removing it made human cells wear out sooner and made blood vessel disease in mice worse. Adding more of it protected against stress. So GPNMB is not just a harmless tag.
The same group's mechanistic follow-up, in human endothelial cells and mice. Depleting GPNMB shortened the replicative lifespan of human vascular endothelial cells, and depleting Gpnmb in mice impaired vascular function and enhanced atherogenesis, while overexpression protected against stress-induced senescence and attenuated vascular dysfunction. GPNMB is a survival factor maintaining lysosomal integrity in senescent cells, not a neutral surface tag.
- Animal study2025Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction
In mice. A different team built a tiny-particle vaccine against GPNMB. Given as a shot under the skin, it switched on killer immune cells that cleared zombie fat and heart cells in fast-ageing mice on a high-fat diet. Fat handling and heart function improved. A second team got a similar result, still in mice.
Mouse. A separate group built a self-assembling nanovaccine carrying a Gpnmb seno-antigen peptide. After subcutaneous immunisation it activated CD8-positive T cells and selectively eliminated senescent adipocytes and cardiomyocytes in high-fat-diet progeroid mice, improving adipose metabolic measures and cardiac function. Independent replication of the concept, still in mice.
Common questions
Has Senolytic vaccine (anti-GPNMB) been tested in people?
Not in any study cited here. Senolytic vaccine (anti-GPNMB) is a vaccine that trains the immune system to attack GPNMB, a protein found in high amounts on worn-out 'zombie' cells. In mice it removed cells carrying GPNMB and helped male mice bred to age too fast live longer. There is no human study.
What is the Senolytic vaccine (anti-GPNMB) dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 3 animal studies, no human study
Is Senolytic vaccine (anti-GPNMB) FDA-approved?
Not approved anywhere and not in any registered human trial. It is a result in mice, published in a scientific journal, not a product.
Is there an anti-aging vaccine?
Not for people. A Japanese team published a mouse result where a vaccine against GPNMB cleared zombie cells and helped male mice bred to age too fast live longer. No human study of it exists.
Did it extend lifespan?
In male mice bred to age abnormally fast. The paper does not report longer life in normal mice, and it does not report it in females.
Why target GPNMB instead of using a senolytic drug?
The authors' argument is that most senolytic drugs block survival switches that healthy cells also use, so harm to healthy cells is a worry. A tag on the cell surface lets the immune system do the picking instead.
What is the catch?
GPNMB is not only on zombie cells. The same team later showed it helps those cells survive by protecting their lysosomes, and removing it made blood vessel disease worse in mice. You would be vaccinating against a protein that is doing a job.
When might this reach people?
Nobody can honestly give a timeline. There is no registered study and no published human safety work. Anything beyond that is guessing.